Pol Polyprotein - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Pol Polyprotein - Pipeline Review, H1 2016

Pol Polyprotein - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Pol Polyprotein - Pipeline Review, H1 2016
Published Jun 30, 2016
52 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Pol Polyprotein - Pipeline Review, H1 2016, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
- The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
- The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Pol Polyprotein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline pr

  
Source:
Document ID
GMDHC0243TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Pol Polyprotein Overview61
Therapeutics Development73
  Pol Polyprotein Products under Development by Stage of Development71
  Pol Polyprotein Products under Development by Therapy Area81
  Pol Polyprotein Products under Development by Indication91
Pol Polyprotein Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Pol Polyprotein Products under Development by Companies122
Pol Polyprotein Products under Development by Universities/Institutes142
Pol Polyprotein Therapeutics Assessment165
  Assessment by Monotherapy/Combination Products161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Pol Polyprotein Companies Involved in Therapeutics Development213
  GeoVax Labs, Inc.211
  Inovio Pharmaceuticals, Inc.221
  Johnson &Johnson231
Pol Polyprotein Drug Profiles2414
  GOVXB-11 Drug Profile243
  GOVXC-11 Drug Profile271
  GOVXC-21 Drug Profile281
  HIV [serotype Ad26] (tetravalent) vaccine Drug Profile291
  HIV-1 (bivalent) vaccine Drug Profile301
  HIV-1 vaccine 11 Drug Profile311
  HIV-1 vaccine 5 Drug Profile321
  PENNVAX-B Drug Profile333
  PENNVAX-GP Drug Profile362
Pol Polyprotein Dormant Projects381
Pol Polyprotein Featured News &Press Releases3912
  May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11391
  Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant401
  Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates401
  Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine411
  Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine421
  Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress421
  Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program431
  Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases441
  Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV451
  Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data461
  Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health471
  Jan 23, 2014: GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases471
  Jan 13, 2014: GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients481
  Oct 09, 2013: GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV491
  Jan 10, 2013: GeoVax Announces Enrollment Completion For Phase I/II Clinical Trial For HIV/AIDS Therapeutic Vaccine501
Appendix512
  Methodology511
  Coverage511
  Secondary Research511
  Primary Research511
  Expert Panel Validation511
  Contact Us511
  Disclaimer521

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Pol Polyprotein - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pol-Polyprotein-Pipeline-Review-H1-2016-2088-16120>
  
APA:
Global Markets Direct - Market Research. (2016). Pol Polyprotein - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pol-Polyprotein-Pipeline-Review-H1-2016-2088-16120>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.